Atorvastatin in the Recipient's Kidney Graft From a Living Donor

• Status: Completed
• Trial end date: 2018-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Renal insufficiency is a priority disease in the health system, which may require renal replacement therapy based on kidney transplantation, which is considered as therapy of choice. During the procedure of kidney transplantation, the body is subjected to ischemia-reperfusion damage that generates late complications related to graft function.

Recently the anti-inflammatory and immunomodulatory effects of statins have been emphasized, which could be beneficial in kidney transplantation.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Instituto Mexicano del Seguro Social
• Treatments: Atorvastatin; Atorvastatin Calcium

Criteria

Donors Inclusion Criteria:

• Accepted as kidney donor

• Voluntary participation

• Informed consent accepted

• 85% fulfillment of atorvastatin treatment

• Entitlement to the Mexican Institute of Social Security

Donors Exclusion Criteria:

• Hypersensibility to Atorvastatin

• Smoking

Recipients Inclusion Criteria:

• Accepted as kidney recipient

• Entitlement to the Mexican Institute of Social Security

Recipients Exclusion Criteria:

• Patients who dropped out from study or withdrew the informed consent

• Insufficient kidney biopsy